OBAMA 2008:”I’LL FIX EVERYTHING-IT’S EASY” OBAMA 2011″IT’S SO BAD I NEED MORE TIME”-WHICH IS the BIGGER LIE?
Question by AntiPc-inHD: OBAMA 2008:”I’LL FIX EVERYTHING-IT’S EASY” OBAMA 2011″IT’S SO BAD I NEED MORE TIME”-WHICH IS THE BIGGER LIE?
In order to get elected in 2008 the President campaigned on how intelligent he was-and due to that he could fix everything…..fix the economy-fix secret back door meetings-fix too many lobbyists-fix Iran issues. So enough people bought the goods he was selling to get him elected. NOW that appears his presidency failed-he and his minions have changed their tune to: “We didn’t know it was this bad-so give us four more years.” If he was so smart as he promised to get elected-why DIDN’T he know it was “this bad.”? Isn’t the truth that the honest 2011 campaign should say “We didn’t know that we don’t know what we’re doing?”
Best answer:
Answer by Jimmy Whispers MMXII
Yes, i agree his statement of 2008 was unrealistic and so is much of his views, but try listening to his competitors speak, they’re the most unrealistic bunch I’ve ever seen.
Know better? Leave your own answer in the comments!
PropThink: Titan Files NDA on Probuphine; Partner Waits
Filed under: drug treatment news 2011
Various posters of the data have been presented at the American College of Neuropsychopharmacology in December 2009 (ACNP Poster-1), the International Society of Addiction Medicine in September 2011 (ISAM Poster-2), and the American Society of …
Read more on Reuters
Allon Therapeutics releases Q3 operating results and provides corporate update
Filed under: drug treatment news 2011
Allon also reported that it is on track to advance toward commercialization of its lead neuroprotective drug candidate davunetide as a potential treatment for progressive supranuclear palsy (PSP), a rapidly progressing and fatal degenerative brain …
Read more on The Herald | HeraldOnline.com
The Prostate Cancer Drug Market Will More than Double, Increasing from .1 …
Filed under: drug treatment news 2011
The Pharmacor Prostate Cancer advisory service finds that, following its U.S. and European launch in 2011, Zytiga has quickly become the treatment of choice for docetaxel (Sanofi's Taxotere, generics)-pretreated metastatic castrate-resistant prostate …
Read more on The Herald | HeraldOnline.com